drugset / Trial / NCT05923424
A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults
RandomizedSequentialQuadruple-blindTreatment
Summary
The purpose of this study is to learn about the safety and tolerability of different doses of REGN17092 administered with a needle either under the skin (called "subcutaneous") or into a vein (called an "infusion") in healthy participants. This is the first time that REGN17092 will be given to people. Other aims are to assess: * How much of the study drug is in the blood at different times * Whether the body makes its own antibodies against the study drug (which could make the drug less effective or lead to side effects)
Timeline
- Start
- 2023-11-28
- Primary completion
- 2025-03-04
- Completion
- 2025-03-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | REGN17092 | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.